Skip to main content
Premium Trial:

Request an Annual Quote

Complete Genomics, Erasmus Collaborate on Cancer and Congenital Malformations

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) –Complete Genomics today announced it is expanding a collaboration with Erasmus University Medical Center.

Under the expansion, the Mountain View, Calif.-based firm will sequence 250 DNA samples over the next 12 months. The samples will be from patients with leukemia and other cancers, as well as congenital malformations such as craniosynostosis.

The partners also are working together on other undisclosed projects, and as part of their collaboration, Complete Genomics has access to Erasmus MC's bioinformatics training center for customer training.

Additional expertise in technology and data management is being co-developed through partnerships with companies such as Ingenuity, Biobase, Tibco/Spotfire, Oracle, and VX Company.

Financial terms of the deal were not disclosed.

"We decided to focus our research efforts with Complete Genomics on diseases where the current technology has not been able to identify the genetic variants responsible," Peter J. van der Spek, head of bioinformatics at Erasmus MC, said in a statement. "Its complete human genome sequencing service will allow us to study genetic variations at a higher resolution and greater sensitivity than has been previously possible."

He added that it is expected that the collaboration will result in new methods and tools to improve patient stratification for targeted treatments.

Clifford Reid, CEO of Complete Genomics, said, "We hope that by furthering its understanding of the genetics of these complex diseases, Erasmus MC can be at the forefront of developing better diagnostic screens that form the basis for genetic testing in monogenetic diseases and targeted treatment development for diseases such as cancer."

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.